Interim report January - September 2021
APPROVAL FROM THE EMA´s PEADIATRIC COMMITTEENINE MONTH PERIOD (JAN-SEP 2021) · EBITDA SEK -12.9 million (-13.8) * · Operating profit (EBIT) SEK -14.8 million (-15.7) * · Profit after tax SEK -12.2 million (-13.3) * · Total profit SEK 11.4 million (-13.3) ** · Diluted earnings per share SEK 0.26 (-0.71) ** · Cash and cash equivalents amounted to SEK 111.4 million (30.0) THIRD QUARTER (JUL-SEP 2021) · EBITDA SEK -4.0 million (-4.6) * · Operating profit (EBIT) SEK -4.7 million (-5.2) * · Profit after tax SEK -3.9 million (-4.7) * · Total profit SEK -3.9